[Inhibitory effects of Forskolin on hepatic metastasis from human colon cancer in nude mice].
Platelet aggregation has been believed to play an important role in implantation of tumor cells into the target organ during the early phase of tumor metastasis. In the present study, the effects of Forskolin, a strong platelet aggregation inhibitor, on experimental hepatic metastasis from human colon cancer (HT29LMM) in nude mice and inhibitory effects of Forskolin on platelet aggregation in the presence of tumor cells were evaluated. A hepatic metastasis model was established by intrasplenic implantation of 3-4 x 10(6) of HT29LMM human colon cancer cells in nude mice. Intraperitoneally 10mg/kg of Forskolin was given 30 minutes before and 24 hours, after implantation of tumor cells, respectively. The control group received saline instead of Forskolin. Phase of hepatic metastasis has been compared for the total weight of hepatic metastatic lesions and the occupied rate between the Forskolin-given group and the control group. The total weight of hepatic metastasis lesions (0.36 +/- 0.33g (SD) vs 3.36 +/- 1.31g) and the occupied rate (8.22 +/- 7.91% vs 67.9 +/- 23.2%) were significantly low in the Forskolin-given group compared with the control group. In vitro inhibitory effects of Forskolin on platelet aggregation was recognized under the presence of HT291LMM. This study suggests that the platelet aggregation inhibitor drug. Forskolin, inhibits hepatic metastasis from human colon cancer by preventing platelet aggregation during the metastatic tumor formation.